Business Context and Reporting Period
Cytosorbents Corp (CTS) filed a Form 8-K on May 20, 2024, regarding a listing compliance issue. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the status of the company's stock listing.
Material Changes
The material event reported is the receipt of a written notice from Nasdaq stating the company is not in compliance with Listing Rule 5550(a)(2). This non-compliance is due to the common stock trading below $1.00 per share for 30 consecutive business days.
Outlook, Risks, and Management Commentary
- Compliance Period: The company has 180 calendar days from the notice date, until November 16, 2024, to regain compliance.
- Requirements: To comply, the closing bid price must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to the compliance date.
- Delisting Risk: If compliance is not achieved by the deadline and no additional period is granted, the stock will be subject to delisting. The company retains the right to appeal a delisting determination.
- Management Action: Management intends to actively monitor the stock price and consider options to regain compliance, though there is no assurance of success.
Investor Verification Checklist
- Verify the current closing bid price of CTSO to assess proximity to the $1.00 threshold.
- Monitor the company's stock price performance over the next 10 consecutive business days to track progress toward the compliance requirement.
- Review future filings for any announcements regarding reverse stock splits or other corporate actions intended to address the bid price deficiency.
- Check for any updates on the company's appeal rights should the November 16, 2024, deadline be missed.